11月17日，通化金马盘中上涨2.23%，截至11:05，报29.39元/股，成交3.93亿元，换手率1.41%，总市值 284.05亿元。 资金流向方面，主力资金净流出1759.63万元，特大单买入2862.41万元，占比7.28%，卖出4253.98万 元，占比10.82%；大单买入1.15亿元，占比29.36%，卖出1.19亿元，占比30.29%。 通化金马所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：民营医院、工业大麻、 东北振兴、肝炎治疗、中药等。 截至9月30日，通化金马股东户数3.82万，较上期减少3.20%；人均流通股25266股，较上期增加3.31%。 2025年1月-9月，通化金马实现营业收入8.92亿元，同比减少7.88%；归母净利润2496.35万元，同比增长 4.35%。 分红方面，通化金马A股上市后累计派现2.10亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，通化金马十大流通股东中，创新药（159992）位居第七大流通股 东，持股919.30万股，相比上期增加8.78万股。南方中证1000ETF（512100）位居第八大流通股东，持 ...

Core Viewpoint - China National Pharmaceutical Group's stock has experienced a decline of 2.06% on November 17, with a current price of 11.41 CNY per share and a total market capitalization of 17.068 billion CNY [1] Financial Performance - For the period from January to September 2025, China National Pharmaceutical achieved a revenue of 25.894 billion CNY, a year-on-year decrease of 0.79%, while the net profit attributable to shareholders was 455 million CNY, reflecting a year-on-year increase of 1.70% [2] - The company has cumulatively distributed dividends of 3.795 billion CNY since its A-share listing, with 725 million CNY distributed over the past three years [3] Stock Market Activity - As of 09:54 on November 17, the trading volume was 137 million CNY, with a turnover rate of 0.80% [1] - The stock has seen a year-to-date increase of 3.77%, a decline of 0.78% over the last five trading days, a rise of 3.92% over the last 20 days, and an increase of 5.16% over the last 60 days [1] Shareholder Information - As of September 30, 2025, the number of shareholders was 139,700, an increase of 0.69% from the previous period, with an average of 10,704 circulating shares per shareholder, a decrease of 0.69% [2] - The top ten circulating shareholders include Southern CSI 500 ETF, holding 10.9137 million shares, down by 170,800 shares from the previous period, and Hong Kong Central Clearing Limited, holding 8.3204 million shares, down by 3.7371 million shares [3] Business Overview - China National Pharmaceutical is primarily engaged in the production, processing, and trade of pharmaceuticals, with its main business revenue composition being 75.50% from pharmaceutical commerce, 13.26% from international trade, and 7.69% from pharmaceutical manufacturing [1]

Core Viewpoint - Kangyuan Pharmaceutical's stock has experienced fluctuations, with a current price of 16.06 CNY per share and a market capitalization of 9.093 billion CNY, reflecting a year-to-date increase of 17.91% [1] Group 1: Stock Performance - As of November 17, Kangyuan Pharmaceutical's stock price decreased by 2.01% during the trading session [1] - The stock has seen a 1.90% increase over the last five trading days and a 3.81% increase over the last twenty days, while it has declined by 9.01% over the last sixty days [1] Group 2: Financial Performance - For the period from January to September 2025, Kangyuan Pharmaceutical reported a revenue of 2.343 billion CNY, a year-on-year decrease of 24.66% [2] - The net profit attributable to shareholders for the same period was 200 million CNY, reflecting a year-on-year decrease of 44.10% [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Kangyuan Pharmaceutical increased by 17.20% to 40,500 [2] - The average number of circulating shares per shareholder decreased by 14.68% to 13,969 shares [2] - The company has distributed a total of 949.8 million CNY in dividends since its A-share listing, with 345 million CNY distributed over the last three years [3]

Core Viewpoint - The pharmaceutical sector demonstrates defensive strength amid market volatility, with the drug ETF (562050) showing resilience and outperforming the broader market [1][3]. Group 1: Market Performance - On November 14, the Shanghai Composite Index fell by 0.97% to close at 3990.39 points, while the ChiNext Index dropped by 2.82%, erasing previous gains [1]. - The drug ETF (562050) recorded a weekly increase of 3.33%, significantly outperforming the market, where the Shanghai Composite Index declined by 0.18% and the ChiNext Index fell by 3.01% [3]. Group 2: Sector Analysis - Since September, the pharmaceutical sector has experienced over a 10% decline from its peak, but recent trends indicate a recovery, with nearly 2.5 billion yuan (approximately 25 million) invested in pharmaceutical ETFs this week [3]. - The pharmaceutical industry is characterized as a necessity sector with substantial future market potential, driven by an aging population and increasing demand for chronic disease treatments [6]. Group 3: Investment Insights - The fund manager of the drug ETF highlighted that the end of the year is typically a peak season for mergers and acquisitions in the U.S. biopharmaceutical sector, with favorable conditions for innovative drugs expected to continue [5]. - The third-quarter reports indicate a recovery in the innovative drug sector, with several companies returning to profitability, suggesting a shift from research investment to commercialization [6]. - The drug ETF (562050) tracks 50 leading pharmaceutical companies, with a focus on innovative drugs and a 25% allocation to traditional Chinese medicine, which offers a relatively high dividend yield and stable performance [6].

11月14日，大市深度调整，沪指跌0.97%报收3990.39点，创指跌2.82%尽吐上日涨幅。震荡之际，制药 板块彰显防御力！全市场唯一跟踪制药指数的药ETF（562050）盘中逆市飘红，一度冲高1%，场内最 终微跌0.18%，显著跑赢市场。 药ETF（562050）覆盖50大龙头药企，重仓创新药，兼顾中药。今日中药龙头以岭药业领涨3.14%，同 仁堂亦收红；创新药局部活跃，甘李药业、康弘药业涨约2%。恒瑞医药、百济神州-U、片仔癀等龙头 股下跌为主要拖累。 每年年底是美国生物医药收并购最活跃的季节，且明年年初还有JPM大会催化。今年医保谈判，继续对 创新药"暖风劲吹"，在美联储降息的宏观背景下，当下创新药向上机会或已大于向下风险。 基本面亦频传利好。从已公布的三季报数据来看，创新药板块整体实现业绩回暖，多家公司实现扭亏， 创新药龙头百济神州业绩亮眼，反映出行业正从研发投入期加速迈入商业化收获期。 回归根本逻辑，制药是刚需赛道，未来市场空间巨大。我国作为人口大国，随着老年人口比例的不断上 升，对药品的需求也在持续增长，尤其是慢性疾病治疗药物等领域。此外，随着人们生活水平的提高， 对医疗保健的重视程度也日益增 ...

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. has shown a mixed performance in stock price and financial metrics, with a notable increase in net profit despite a slight decline in revenue [1][2]. Financial Performance - As of September 30, 2025, the company reported a revenue of 6.311 billion yuan, a year-on-year decrease of 2.35% [2]. - The net profit attributable to shareholders was 984 million yuan, reflecting a year-on-year increase of 16.88% [2]. - The company has distributed a total of 8.053 billion yuan in dividends since its A-share listing, with 2.092 billion yuan distributed over the past three years [3]. Stock Market Activity - On November 14, the stock price increased by 2.06%, reaching 15.86 yuan per share, with a trading volume of 232 million yuan and a turnover rate of 0.99% [1]. - The stock has seen a year-to-date increase of 12.88%, a 5-day increase of 3.12%, a 20-day decrease of 0.25%, and a 60-day decrease of 0.81% [1]. - The net inflow of main funds was 7.192 million yuan, with significant buying and selling activity from large orders [1]. Shareholder Structure - The number of shareholders increased to 81,300, a rise of 34.45% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 25.62% to 18,383 shares [2]. - Notable institutional holdings include Hong Kong Central Clearing Limited as the fourth-largest shareholder, increasing its stake by 11.93 million shares [3].

Core Viewpoint - The stock of Shouxiangu has shown a slight increase in recent trading sessions, with a notable rise in trading volume and a positive net inflow of funds, indicating investor interest despite a decline in revenue and profit year-on-year [1][2]. Company Overview - Shouxiangu Pharmaceutical Co., Ltd. is located in Wuyi County, Zhejiang Province, and was established on March 3, 1997. It was listed on May 10, 2017. The company specializes in the breeding, cultivation, processing, and sales of valuable traditional Chinese medicinal materials such as Ganoderma and Dendrobium [2]. - The main business revenue composition includes: Ganoderma spore powder products (71.92%), Dendrobium products (15.57%), other products (10.88%), and supplementary products (1.63%) [2]. Stock Performance - As of November 14, the stock price of Shouxiangu increased by 2.16%, reaching 21.30 CNY per share, with a trading volume of 33.55 million CNY and a turnover rate of 0.80%. The total market capitalization is 4.22 billion CNY [1]. - Year-to-date, the stock price has risen by 1.72%, with a 3.60% increase over the last five trading days, a 3.40% increase over the last 20 days, and a 3.75% decrease over the last 60 days [2]. Financial Performance - For the period from January to September 2025, Shouxiangu reported a revenue of 430 million CNY, a year-on-year decrease of 8.88%. The net profit attributable to the parent company was 76.34 million CNY, down 35.67% year-on-year [2]. - Since its A-share listing, Shouxiangu has distributed a total of 436 million CNY in dividends, with 218 million CNY distributed in the last three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Shouxiangu was 22,700, a decrease of 4.31% from the previous period. The average circulating shares per person increased by 4.51% to 8,727 shares [2]. - Among the top ten circulating shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B fund holds 1.2823 million shares, an increase of 82,300 shares compared to the previous period [3].

Core Viewpoint - Wohuah Pharmaceutical's stock has shown a significant increase of 42.06% year-to-date, with a recent price of 6.62 CNY per share, indicating strong market interest and performance [1][2]. Company Overview - Wohuah Pharmaceutical, established on February 9, 2002, and listed on January 24, 2007, specializes in the research, production, and sales of natural plant-based cardiovascular traditional Chinese medicine [1]. - The company's revenue composition includes 69.17% from cardiovascular drugs, 23.46% from musculoskeletal drugs, 3.59% from other categories, 2.97% from antiviral respiratory drugs, and 0.81% from reproductive and urinary system drugs [1]. Financial Performance - For the period from January to September 2025, Wohuah Pharmaceutical reported a revenue of 625 million CNY, reflecting a year-on-year growth of 8.31%, and a net profit attributable to shareholders of 63.995 million CNY, which is a substantial increase of 179.34% year-on-year [2]. - The company has distributed a total of 692 million CNY in dividends since its A-share listing, with 214 million CNY distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Wohuah Pharmaceutical had 41,000 shareholders, an increase of 17.18% from the previous period, with an average of 13,892 circulating shares per shareholder, down by 14.66% [2]. - Notable new institutional shareholders include Baodao Jiuhang Mixed A and Guotai Haitong CSI 500 Index Enhanced A, which are now among the top ten circulating shareholders [3].

Core Viewpoint - Kangyuan Pharmaceutical's stock has shown a mixed performance in recent months, with a year-to-date increase of 17.47% but a decline of 7.08% over the past 60 days, indicating volatility in its market position [1]. Financial Performance - For the period from January to September 2025, Kangyuan Pharmaceutical reported a revenue of 2.343 billion yuan, representing a year-on-year decrease of 24.66%. The net profit attributable to shareholders was 200 million yuan, down 44.10% compared to the previous year [1]. - The company has distributed a total of 949.8 million yuan in dividends since its A-share listing, with 345 million yuan distributed over the last three years [2]. Stock Market Activity - As of November 14, the stock price of Kangyuan Pharmaceutical was 16.00 yuan per share, with a market capitalization of 9.059 billion yuan. The stock experienced a 2.04% increase during the trading session [1]. - The trading volume indicated a net inflow of 2.1421 million yuan from main funds, with large orders accounting for 20.99% of purchases and 15.69% of sales [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased by 17.20% to 40,500, while the average number of circulating shares per person decreased by 14.68% to 13,969 shares [1]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited held 14.478 million shares, an increase of 440,200 shares from the previous period [2]. Business Overview - Kangyuan Pharmaceutical, established on May 8, 1996, and listed on September 18, 2002, is primarily engaged in the research, production, and sales of pharmaceuticals. Its revenue composition includes 58.68% from oral medications, 33.28% from injections, and 8.04% from external applications [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in traditional Chinese medicine [1].

Core Viewpoint - Yiling Pharmaceutical's stock has shown significant growth this year, with a year-to-date increase of 30.17% and a recent surge of 16.72% over the past five trading days [1] Financial Performance - For the period from January to September 2025, Yiling Pharmaceutical reported a revenue of 5.868 billion yuan, a year-on-year decrease of 7.82%, while the net profit attributable to shareholders was 1 billion yuan, reflecting a year-on-year increase of 80.33% [2] - The company has cumulatively distributed 4.455 billion yuan in dividends since its A-share listing, with 1.838 billion yuan distributed over the past three years [3] Stock Market Activity - As of November 13, Yiling Pharmaceutical's stock price reached 20.45 yuan per share, with a trading volume of 1.068 billion yuan and a turnover rate of 3.91% [1] - The company has appeared on the "Dragon and Tiger List" once this year, with a net purchase of 640.503 million yuan on January 6 [1] Shareholder Structure - As of September 30, 2025, Yiling Pharmaceutical had 152,700 shareholders, a decrease of 10.22% from the previous period, with an average of 9,013 circulating shares per shareholder, an increase of 11.38% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder, increasing its holdings by 8.1119 million shares [3]